TuHURA Biosciences, Inc.
NASDAQ•HURA
CEO: N/A
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2013-02-22
N/A
Contact Information
Market Cap
$37.71M
P/E (TTM)
-0.5
37
Dividend Yield
--
52W High
$5.27
52W Low
$0.66
52W Range
Rank54Top 78.1%
2.7
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.7 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
$0.00+0.00%
4-Quarter Trend
FCF
$0.00+0.00%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Kineta Merger Closed June Kineta Merger closed June 30, 2025, adding TBS-2025 asset; recognized $13.6M Goodwill in preliminary allocation.
June Financing Secured $12.6M June 2025 Private Placement secured $12.6M gross proceeds; financing activities provided $13.4M net cash inflow for nine months.
R&D Investment Increased Substantially Nine-month R&D expenses reached $14.5M, increasing $5.1M to support IFx-2.0 and TBS-2025 clinical development.
Risk Factors
Low Cash Reserves Noted Cash reserves stood at $2.7M as of September 30, 2025; substantial doubt on continuing operations without further funding noted.
Operating Losses Widened Significantly Nine-month Net Loss widened to $23.3M from $15.7M year prior; operating loss increased by $11.7M.
FDA Disruptions Risk Delays FDA funding shortages risk hindering review ability, potentially delaying IFx-2.0 approval and commercialization timelines.
Increased G&A Expenses General and administrative expenses rose $6.5M to $9.1M, driven by merger costs and public company compliance expenses.
Outlook
Future Funding Needs Anticipated Expect substantial future funding required via equity, debt, or partnerships; ATM program filed for up to $50.0M post-period.
Advance Key Pipeline Candidates Advance IFx-2.0 Phase 3 trial and plan TBS-2025 Phase 2 trial investigation in mutated NPM1 AML patients.
Liquidity Sufficient Through 2025 Existing capital, bridge loan, and recent financing expected to fund planned operations into the end of 2025.
Peer Comparison
Revenue (TTM)
AGEN$106.83M
$30.08M
$16.33M
Gross Margin (Latest Quarter)
100.0%
100.0%
87.1%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| ARMP | $218.44M | -4.6 | 70.3% | 198.5% |
| CNTX | $166.30M | -6.5 | -30.9% | 0.2% |
| SPRO | $137.47M | -3.1 | -125.9% | 6.2% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 14, 2025|Refer to amended dataForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 14, 2025|Revenue: $0.00+0.0%|EPS: $-0.21+64.5%N/AForm 10-Q - 1 2025
Period End: Mar 31, 2025|Filed: May 15, 2025|Refer to amended dataForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 31, 2025|Revenue: $0.00+0.0%|EPS: $-1.21+89.3%N/AForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 14, 2024|Revenue: $0.00+0.0%|EPS: $-0.01-74.8%N/AForm 10-K - FY 2024
Period End: Jun 30, 2024|Filed: Oct 7, 2024|Refer to amended dataForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 14, 2024|Revenue: $0.00+0.0%|EPS: $-11.52-97.1%N/AForm 10-Q - Q4 2023
Period End: Dec 31, 2023|Filed: Feb 14, 2024|Revenue: $0.00+0.0%|EPS: $-8.27-88.8%N/A